Moleculin Biotech, INC 8-K filings

Moleculin Biotech, Inc. has been notified by Nasdaq of non-compliance with listing rules due to failing to meet the minimum stockholders' equity requirement, initiating a process to regain compliance.

Moleculin Biotech announces its Q1 2025 financial results and provides an update on its clinical programs, including the Phase 3 MIRACLE trial for Annamycin in R/R AML.

Moleculin Biotech's Phase 3 MIRACLE trial for Annamycin in R/R AML receives EMA approval, expanding the trial to nine additional EU countries.

Moleculin Biotech's Special Meeting of Stockholders was cancelled on May 9, 2025, due to the absence of a quorum, despite approximately 70% of voted shares being in favor of the motion.

Moleculin Biotech will release its Q1 2025 financial results on May 13, 2025, followed by a conference call on May 14, 2025, to discuss the results and provide an operational update.

Moleculin Biotech announces that the World Health Organization has approved 'naxtarubicin' as the International Nonproprietary Name (INN) for its drug candidate Annamycin.

Moleculin Biotech announces the grant of two new U.S. patents related to Annamycin, further strengthening its intellectual property position.

Moleculin Biotech presented data at the AACR Annual Meeting 2025, showcasing Annamycin's potential in treating pancreatic cancer and other solid tumors through synergistic combinations with existing therapies.

Moleculin Biotech's Special Meeting of Stockholders has been adjourned for a second time due to the absence of a quorum, now rescheduled for May 9, 2025.

Moleculin Biotech, Inc. released a corporate presentation on its website on April 21, 2025.

Moleculin Biotech announces that an abstract regarding its next-generation anthracycline, Annamycin, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025.

Moleculin Biotech's Special Meeting of Stockholders was adjourned to April 25, 2025, due to the absence of a quorum.

Moleculin Biotech has initiated its Phase 3 pivotal MIRACLE trial, dosing the first patient to evaluate Annamycin in combination with Cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML).

Moleculin Biotech releases an updated corporate presentation on its website, providing insights into the company's current status and future plans.

Moleculin Biotech reports its full year 2024 financial results and provides a corporate update, highlighting progress in its Phase 3 MIRACLE trial and expected data readouts.

Moleculin Biotech announces a Notice of Intent to Grant for a European patent application related to its liposomal Annamycin formulation, enhancing global exclusivity for this potential cancer treatment.

Moleculin Biotech secures $3.5 million through a registered direct offering and private placement to fund working capital and general corporate purposes.

Moleculin Biotech incentivizes warrant holders to exercise existing warrants, generating approximately $5.8 million in gross proceeds and issuing new warrants for future common stock purchases.

Moleculin Biotech announces positive FDA feedback allowing for a reduced size in its Phase 3 MIRACLE trial for Annamycin in R/R AML, potentially accelerating the timeline for new drug approval.

Moleculin Biotech has received its first European regulatory approval to begin recruiting for its Phase 3 MIRACLE trial evaluating Annamycin in combination with Cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML).

Moleculin Biotech entered into a waiver and consent agreement with an investor, modifying warrant terms and agreeing to a cash payment in exchange for waiving restrictions on a Variable Rate Transaction.

Moleculin Biotech filed an amended 8-K to correct a hyperlink error in a previous filing related to a script from a virtual investor event.

Moleculin Biotech is progressing towards the launch of its MIRACLE pivotal study for relapsed/refractory AML, with the first patient expected to be treated this quarter and a key data readout anticipated by year-end.

Moleculin Biotech's CEO, Walter Klemp, discussed the progress of the Phase 3 MIRACLE trial for Annamycin in treating relapsed or refractory acute myeloid leukemia (AML) during a virtual investor segment.

Moleculin Biotech reports positive progress in its Annamycin clinical trials, including accelerated timelines for Phase 3 data readouts and strong Phase 2 results in AML.

Moleculin Biotech has released a new corporate presentation, which is now available on their website, as part of a Regulation FD disclosure.

Moleculin Biotech has released an updated corporate presentation, which is now available on their website.

Moleculin Biotech's Annamycin shows significant activity against drug-resistant acute myeloid leukemia (AML) in preclinical studies, with potential for improved patient outcomes.

Moleculin Biotech announced new findings indicating that Annamycin can overcome resistance to Venetoclax in acute myeloid leukemia (AML), with promising preclinical and clinical data.

Moleculin Biotech released a new corporate presentation on November 18, 2024, which is now available on the company's website.